Join Tvardi Therapeutics for a virtual key opinion leader (KOL) webinar featuring Randy Longman, MD, PhD (Weill Cornell Medicine), who will join Tvardi management to discuss the current treatment landscape in ulcerative colitis (UC) and the persistent unmet needs that remain despite recent clinical advances and currently approved therapies.

The event will feature new data from Tvardi and a review of the Phase 1 healthy volunteer results supporting the potential of TTI-109 in UC. The discussion will explore the scientific rationale for targeting STAT3, a convergent node implicated in multiple pathways that contribute to the pathogenesis and persistence of UC. Tvardi management will also discuss the planned clinical development strategy for TTI-109.

Dr. Longman will provide his perspective on the clinical relevance of the findings and how a STAT3 inhibitor could ultimately fit within the UC treatment paradigm.

A live question and answer session will follow the formal presentations.